Title:
DEUTERATED COMPOUND AND USE THEREOF IN CANCER TREATMENT
Document Type and Number:
WIPO Patent Application WO/2021/037198
Kind Code:
A1
Abstract:
The present invention provides a compound of formula (I), a pharmaceutically acceptable salt or ester thereof, a pharmaceutical composition thereof, and uses of the compound and the pharmaceutical composition of the present invention for inhibiting or regulating the activity of tyrosine kinases and treating disease symptoms or conditions, including cancer, mediated by tyrosine kinases.
Inventors:
LV JIASHENG (CN)
GU JIAMIN (CN)
CHEN GANG (CN)
ZHANG QIGUO (CN)
SUN CHENGYONG (CN)
KONG XIANQI (CN)
GU JIAMIN (CN)
CHEN GANG (CN)
ZHANG QIGUO (CN)
SUN CHENGYONG (CN)
KONG XIANQI (CN)
Application Number:
PCT/CN2020/112062
Publication Date:
March 04, 2021
Filing Date:
August 28, 2020
Export Citation:
Assignee:
RISEN SUZHOU PHARMA TECH CO LTD (CN)
International Classes:
C07D401/06; A61K31/4439; A61K31/675; A61P35/00; C07D401/14; C07F9/6558; C07F9/6574
Foreign References:
| CN110372598A | 2019-10-25 | |||
| US20090062347A1 | 2009-03-05 | |||
| CN108467385A | 2018-08-31 | |||
| CN102040588A | 2011-05-04 | |||
| CN104788372A | 2015-07-22 | |||
| CN104211683A | 2014-12-17 | |||
| CN103159680A | 2013-06-19 |
Other References:
ZHANG HUI, LI MINGHUA, QIAO YUFENG: "Graphical Synthetic Routes of Axitinib", CHINESE JOURNAL OF PHARMACEUTICALS, vol. 45, no. 9, 30 September 2014 (2014-09-30), pages 896 - 898, XP055787156, ISSN: 1001-8255
Attorney, Agent or Firm:
CHINA PAT INTELLECTUAL PROPERTY OFFICE (CN)
Download PDF: